Berbamine (dihydrochloride)
CAT:
804-HY-N0714A-01
Size:
200 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
Berbamine (dihydrochloride)
- CAS Number: 6078-17-7
- UNSPSC Description: Berbamine dihydrochloride is an inhibitor of NF-κB activity with remarkable anti-myeloma efficacy.
- Target Antigen: Apoptosis; Autophagy; NF-κB
- Type: Natural Products
- Related Pathways: Apoptosis;Autophagy;NF-κB
- Applications: Cancer-programmed cell death
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/Berbamine-dihydrochloride.html
- Purity: 96.62
- Solubility: DMSO : ≥ 100 mg/mL|H2O : 25 mg/mL (ultrasonic)
- Smiles: COC1=C(OC2=CC([C@]3([H])CC(C=C4)=CC=C4O5)=C(CCN3C)C=C2OC)C([C@@]6([H])CC7=CC=C(O)C5=C7)=C(CCN6C)C=C1OC.Cl.Cl
- Molecular Weight: 681.65
- References & Citations: [1]Liang Y, et al. Berbamine, a novel nuclear factor kappaB inhibitor, inhibits growth and induces apoptosis in human myeloma cells. Acta Pharmacol Sin. 2009 Dec;30(12):1659-65.|[2]Meng Z, et al. Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca2+/calmodulin-dependent protein kinase II. Mol Cancer Ther. 2013 Oct;12(10):2067-77.Cell Stress Chaperones. 2021 Jan 6.|J Ethnopharmacol. 2022 Dec 7;303:116025.|J Periodontol. 2024 Jul 5.|Patent. US20220017867A1.|Biomed Pharmacother. 2024 Aug 15:179:117309.|Chemrxiv. Oct 12, 2021.|Drug Des Devel Ther. 2022 Jan 11;16:129-141.|Mol Pharm. 2022 Oct 21.|Pharmaceuticals. 2024 Nov 25.|PLoS Pathog. 2023 Jan 26;19(1):e1011131.
- Shipping Conditions: Room Temperature
- Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
- Clinical Information: Launched